Anxiety and Depression Management in Parkinson's Disease

Anxiety and depression are among the most disabling non-motor manifestations of Parkinson’s disease, affecting up to half of all patients and exerting a profound impact on quality of life. Their management requires a multipronged approach that encompasses dopaminergic and non-dopaminergic pharmacotherapy, cognitive behavioural therapy and mindfulness-based interventions, and, in select cases, neuromodulation techniques such as deep brain stimulation or transcranial magnetic stimulation. Recent advances have elucidated the cortico-limbic and striatal circuits that underlie these mood disturbances, enabling more precise risk stratification and the development of tailored treatment algorithms. Integrating neuroimaging and electrophysiological biomarkers with psychosocial support has become central to optimising outcomes and reducing the global burden of neuropsychiatric comorbidity in Parkinson’s disease.

Research from Nature Portfolio

Recent work has used resting-state functional MRI to reveal that depression, anxiety and apathy in Parkinson’s disease each correspond to distinct patterns of network dysfunction. Increased connectivity between limbic regions and orbitofrontal cortex underlies depressive symptoms, whereas heightened limbic–orbitofrontal signalling alongside reduced prefrontal regulation characterises anxiety, and separate fronto-striatal disconnections underpin apathy. This disaggregation of symptom-specific networks offers an anatomical framework for tailored interventions targeting precise circuits.

Anxiety and Depression Management in Parkinson's Disease publication trend

The graph below shows the total number of articles in anxiety and depression management in parkinson's disease across all publications each year (not limited to Nature Index journals).

Technical terms

Cortico-limbic system: Neural network connecting cortex and limbic structures that regulates emotion and stress responses.

Functional connectivity: Statistical dependence between spatially remote neurophysiological events, often measured by MRI or EEG.

Electroencephalography (EEG): Non-invasive recording of electrical activity along the scalp to assess brain function.

Cognitive behavioural therapy: Psychotherapeutic approach that addresses maladaptive thoughts and behaviours to alleviate mood disorders.

Mindfulness-based intervention: Training programme that cultivates non-judgemental awareness of the present moment to reduce stress and improve mental health.

References

1. Separate neural representations of depression, anxiety and apathy in Parkinson’s disease. Scientific Reports (2017).
2. Electrophysiological signatures of anxiety in Parkinson’s disease. Translational Psychiatry (2024).
3. Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies. npj Parkinson's Disease (2023).
4. Stress and mindfulness in Parkinson’s disease – a survey in 5000 patients. npj Parkinson's Disease (2021).
5. A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson’s disease. BMC Psychiatry (2014).
6. Impact of Anxiety on Quality of Life in Parkinson′s Disease. Parkinson's Disease (2011).